Excorp Medical
Excorp Medical is a private Minneapolis-based medical device company developing the Bioartificial Liver Support System (BLSS), an extracorporeal hollow fiber bioreactor using primary porcine hepatocytes to provide temporary metabolic support for patients in acute liver failure. The FDA Orphan Drug-designated product is in pre-Phase III clinical development.
- Company typePrivate
- Founded1995
- HeadquartersMinneapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Excorp Medical does
Excorp Medical, Inc. is a private medical device company founded in 1995 and headquartered in Minneapolis, Minnesota, that has developed the Bioartificial Liver Support System (BLSS), an extracorporeal blood purification system intended to provide temporary metabolic support for patients in acute liver failure. The system continuously withdraws whole venous blood from the patient, regulates temperature, oxygenates to arterial levels, adjusts pH, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning blood to the patient. The 100 kD nominal cutoff hollow fiber membrane serves as an immunoisolation barrier between species, allowing xenogeneic metabolic activity without direct blood contact. The platform technology is extendable beyond hepatocytes to pancreatic islets and other endocrine cell applications. Each therapeutic procedure is designed to last approximately 12 hours and may be repeated 2-3 times per liver failure episode.
The company targets liver transplant centers and academic medical centers in the US and Asia. The primary clinical use cases are bridging acute liver failure patients to native liver regeneration or to liver transplantation, with secondary use cases in post-liver-resection support and multi-organ failure scenarios. Phase I/II clinical trials have been completed at the University of Pittsburgh Medical Center under a 10-year collaboration with the Thomas E. Starzl Transplantation Institute, and the product has received FDA Orphan Drug Designation, providing seven-year market exclusivity upon approval. A planned Phase III trial has been described involving 150 patients across six US centers, but no FDA marketing approval or commercial sales have been disclosed.
The business model is enterprise field sales to hospitals, with revenue expected to be generated from sale of the BLSS device hardware and single-use bioreactor cartridges on a per-treatment basis, subject to hospital procurement and payer reimbursement. The company has established wholly owned subsidiaries in Hong Kong (Excorp Medical (HK), Ltd., 2008) and Wu'xi, China (Wu'Xi Excorp Biotech Co., Ltd., 2008), and is pursuing local manufacturing partnerships — including a planned joint venture with Shinva Medical Instrument in China and a manufacturing facility in Hyderabad, India — to localize bioreactor production for target markets. Revenue has not been publicly disclosed, and the company remains in pre-commercial clinical stage.
Excorp Medical firmographics
Firmographics- Name
- Excorp Medical
- Legal name
- Excorp Medical, Inc.
- Website
- https://excorp.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Excorp Medical is a private Minneapolis-based medical device company developing the Bioartificial Liver Support System (BLSS), an extracorporeal hollow fiber bioreactor using primary porcine hepatocytes to provide temporary metabolic support for patients in acute liver failure. The FDA Orphan Drug-designated product is in pre-Phase III clinical development.
- Ownership category
- akta.pro rank
Excorp Medical industry classification
Industry- Product category
- Bioartificial Liver Medical Devices
- akta.pro primary industry
- Hepatology & Liver Disease (HLAKAEAB)
- akta.pro secondary industry
- Transplant Hepatology (HLAKAEAK)
Keywords
Where Excorp Medical is headquartered
LocationHeadquarters
- HQ city
- Minneapolis
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Excorp Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
Revenue model
- Bioartificial Liver System Products and Procedures: Revenue generated from sale of the BLSS device and single-use bioreactor cartridges to hospitals and liver transplant centers. Treatments are expected to be 12 hours in duration and repeated 2-3 times during a given episode of liver failure, creating recurring revenue potential per patient episode.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Excorp Medical product offering
Product offeringCore offering
Excorp Medical develops and intends to commercialize the Bioartificial Liver Support System (BLSS), an extracorporeal medical device that continuously withdraws a patient's venous blood, oxygenates and conditions it, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning the blood to the patient. The system is designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed, with treatment sessions lasting approximately 12 hours and repeated 2-3 times per liver failure episode.
Product overview
Excorp Medical is a medical device company with a single unified product offering: the Bioartificial Liver System (BLSS). The system is an extracorporeal liver assist device designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed. The company operates through subsidiaries in China (Wu'xi Excorp Biotech Co., Ltd.) and Hong Kong (Excorp Medical (HK), Ltd.) for manufacturing and regional operations. The BLSS is protected by US and European patents and has received FDA Orphan Drug Designation.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioartificial Liver Support System (BLSS)
Quantifiable outcome
- Phase I/II clinical trials completed demonstrating safety and proof of efficacy principle
- +3 more outcomes
Companies that use Excorp Medical
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles1 record
Excorp Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Excorp Medical partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor, core and major.
- ChinaBio Investor ForumminorSelected as 1 of 20 companies to present at ChinaBio Investor Forum 2009 in Hong Kong for investor outreach and partnership development.
- University of Pittsburgh - Thomas E. Starzl Transplantation Institutecore10-year collaboration with the leading university in liver transplantation and tissue engineering for development of the Bioartificial Liver System. Dr. Jack Patzer serves as Principal Investigator and Coordinator of the Bioartificial Liver Program. Dr. George Mazariegos led preclinical studies and Phase I/II clinical trial evaluation.
- Hong Kong University Clinical Trials CentrecorePartnership for protocol development and clinical trial operations in Hong Kong. Lead investigators selected and protocol development ongoing for Phase I/II clinical trials.
- Shinva Medical Instrument Co., Ltd (新华医疗器械股份有限公司)majorPlanned joint venture (Shinva Excorp Bioscience Corp., Ltd.) in Zibo, Shandong Province, China for manufacturing and distribution of bioartificial liver products in China.
- The Chinese University of Hong KongminorResearch and academic partnership in Hong Kong for liver failure research and clinical development.
- Hong Kong Science & Technology ParksminorExcorp Medical (HK), Ltd. admitted to Hong Kong Science & Technology Parks in December 2008, providing access to infrastructure and biotech ecosystem support.
- National Institute of Animal Biotechnology (India)minorPartnership announced in 4th quarter 2013 for animal biotechnology collaboration supporting bioartificial liver development.
- Acharya Nagarjuna University (India)minorFormal relationship announced in 3rd quarter 2013 for research collaboration in India.
Scale indicators9 records
Recent moves11 records
Expansion highlights5 records
Excorp Medical competitors and assessment
Company assessmentDirect peers
- Vital Therapies: Vital Therapies developed the ELAD (Extracorporeal Liver Assist Device) bioartificial liver system using human liver-derived cell lines (C3A). It was the most direct US competitor in bioartificial liver technology, though it ceased operations after Phase III failure in 2018, illustrating the difficulty of this therapeutic category.
Broad incumbents
- Terumo BCT: Terumo BCT is a major supplier of blood component collection, processing, and cell therapy manufacturing systems. As an established extracorporeal blood processing technology provider, it represents both a potential supplier and a strategic partner or acquirer for cell-based liver support platforms.
- Baxter International (MARS system): Baxter markets the MARS (Molecular Adsorbent Recirculating System) albumin dialysis liver support therapy through its acquired Gambro business. MARS is the most clinically established non-cell-based extracorporeal liver support system and competes for the same hospital budget as Excorp's BLSS.
- Fresenius Medical Care (Prometheus system): Fresenius developed and commercialized the Prometheus fractionated plasma separation and adsorption (FPSA) liver support system. As the global dialysis leader, Fresenius represents an entrenched incumbent in extracorporeal blood purification therapies and a potential strategic acquirer of cell-based alternatives.
Emerging players
- Miromatrix Medical: Miromatrix is developing bioengineered whole organs and tissues using its proprietary decellularization/recellularization platform, including liver applications. Its work on functional liver constructs is conceptually adjacent to Excorp's extracorporeal bioreactor approach.
- Organovo: Organovo is developing 3D-bioprinted human liver tissue for therapeutic and research applications, including potential use in liver disease and toxicity testing. While targeting a different technology modality, it represents an adjacent emerging approach to cell-based liver therapy.
- Promethera Biosciences: Promethera develops liver-derived cell therapies (Heparesc and other allogeneic hepatic progenitor cell products) for liver disease, including acute and chronic indications. It represents an adjacent cell-therapy approach to addressing liver failure patients.
- Cytonet: Cytonet (formerly known as Cytonet GmbH) developed cell-based liver therapies using isolated human liver cells for extracorporeal application in patients with acute liver failure. It is the closest European cell-based liver support peer to Excorp's approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Excorp Medical social profiles
Digital presenceExcorp Medical compliance and trust
Trust signalCompliance1 record
Excorp Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Excorp Medical leadership team
Management profileNumber of profiles
Profiles11 records
Excorp Medical subsidiaries and ownership
Company hierarchySubsidiaries4 records
Excorp Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Excorp Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Excorp Medical
What does Excorp Medical do?
Excorp Medical develops and intends to commercialize the Bioartificial Liver Support System (BLSS), an extracorporeal medical device that continuously withdraws a patient's venous blood, oxygenates and conditions it, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning the blood to the patient. The system is designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed, with treatment sessions lasting approximately 12 hours and repeated 2-3 times per liver failure episode.
Is Excorp Medical a public or private company?
Excorp Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Excorp Medical founded?
Excorp Medical was founded in 1995. It employs 11 to 50 people.
Where is Excorp Medical based?
Excorp Medical is headquartered in Minneapolis, United States, in the North America region.
How does Excorp Medical make money?
One revenue line is on record: bioartificial Liver System Products and Procedures.
Who are Excorp Medical's main competitors?
Vital Therapies is listed as a direct peer. Broad incumbents are Terumo BCT, Baxter International (MARS system) and Fresenius Medical Care (Prometheus system). Emerging players are Miromatrix Medical, Organovo, Promethera Biosciences and Cytonet.
Does Excorp Medical have an API?
No public API is recorded for Excorp Medical.
What industry is Excorp Medical in?
Excorp Medical's product category is Bioartificial Liver Medical Devices. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease, with a secondary code of HLAKAEAK, Transplant Hepatology.